iShares Biotechnology ETF

IBB

Market cap $8.58B

Designed to provide broad exposure to the Health Care ETFs category of the market, the iShares Biotechnology ETF (IBB) is a smart beta exchange traded fund launched on 02/05/2001.

Biotech is quietly stepping into a leadership role here in early 2026 — and the move is not happening in a vacuum. After years of underperformance from 2021 through much of 2024, the sector began a powerful rebound in the second half of 2025.

Designed to provide broad exposure to the Healthcare - Biotech segment of the equity market, the iShares Biotechnology ETF (IBB) is a passively managed exchange traded fund launched on February 5, 2001.

Dividend stocks have sharply outperformed AI-related tech stocks since November 2025, reversing a multi-year trend. I see the rally in dividend ETFs like SCHD as overextended, prompting a pause in new purchases despite recent gains. AI is likely to benefit users more than makers, with sectors like banks, energy, and consumer staples positioned as early winners.

Sold 24,270 shares of IBB; estimated trade value of $3.50 million based on quarterly average pricing. Net position value decreased by $3.50 million.

iShares Biotechnology ETF is rated a BUY, offering a balanced entry into biotech with large-cap stability and strong recent performance. IBB benefits from catalysts including accelerating M&A and AI-driven R&D efficiencies and more dovish Fed policy, positioning the sector for outperformance in 2026. The fund's market cap-weighted structure emphasizes cash-flow positive giants, better managing idiosyncratic risk compared to equal-weighted biotech peers.

iShares Biotechnology ETF (IBB) earns a reiterated hold rating as it consolidates near all-time highs with balanced risk/reward. IBB's valuation is fair at a 19x P/E and low 3% EPS growth, resulting in an unimpressive PEG ratio. Technical momentum has slowed, with potential consolidation around $180 and long-term support near $150.

NVIDIA Corp.'s (NASDAQ: NVDA) and Eli Lilly and Co.'s (NYSE: LLY) newly announced $1 billion AI co-innovation lab underscores how artificial intelligence is spreading beyond data centers into medicine, and ETF investors are beginning to price that into thematic funds.

Publicly traded drug developers sold more than $13 billion of shares in the fourth quarter, the most in more than four years.

Biotech rally gains steam on valuations, rate cuts, FDA wins & M&A. IBB, XBI, CANC and IDNA are ETFs near one-year highs.